Madrigal Pharmaceuticals to Join Morgan Stanley 22nd Annual Global Healthcare Conference

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol MDGL, has announced its participation in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Thursday, September 5, 2024, at 10:45 A.M. Eastern Time. The company's presentation will be broadcast live via a webcast, accessible through their Investor Relations Events page. Additionally, a replay of the webcast will be made available following the event.

Madrigal Pharmaceuticals is dedicated to developing innovative treatments for nonalcoholic steatohepatitis (NASH), a severe liver condition with significant unmet medical needs. The company's lead product, Rezdiffra (resmetirom), is an oral medication taken once daily. It functions as a liver-specific THR-β agonist, targeting critical underlying factors that contribute to NASH. This drug represents a significant advancement in the treatment of this widespread and challenging liver disease.